The Globe and Mail reports in its Friday, May 15, edition that Raymond James analyst Daniel Magder has downgraded his recommendation for Boralex to "market perform" from "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Magder gave his share target a 75-cent trim to $37.25. Analysts on average target the shares at $36. Mr. Magder says in a note: "With the upcoming shareholder vote, which we anticipate will approve the transaction, Boralex is moving toward closing its take-private transaction with Brookfield Renewables (Brookfield) and Caisse de depot et placement du Quebec for cash consideration of $37.25 per share. Post vote and court approval of the transaction, the focus will be on obtaining regulatory approvals as the company marches toward a 4Q26 closing." The Globe reported on March 4, 2025, that Mr. Magder was keeping his "outperform" recommendation for Boralex intact. The shares were then going for $29.12. The Globe reported on Jan. 22, 2026, that National Bank Financial analyst Baltej Sidhu had reiterated his "outperform" recommendation for Boralex. The shares were then going for $25.71.